1. NARCOMS - Patients Perspectives in Changing Medications in MS

  2. Why Do Clinical Trials

  3. Long Term BG-12

  4. Statins for the Treatment of Secondary Progressive MS

  5. Stem Cell Research in MS

  6. Biomarkers in MS

  7. How To Help Cognitive Function

  8. Day Two Introduction

  9. ECTRIMS 2012 Intro

  10. Update on BG12

  11. Welcome To Lyon

  12. Ashley's CMSC Update, Part 3

  13. Ashley's CMSC Update, Part 2

  14. Ashley's CMSC Update, Part 1

  15. Goodbye from San Diego

  16. Thank You from CMSC

  17. Ashley Interviews Clay Walker

  18. Self-Efficacy in MS

  19. Study on Pseudobulbar Affect

  20. Multiple Sclerosis Cost

  21. Social Security Disability and MS

  22. Long-Term Use of Interferon Beta-1a

  23. All About CMSC

  24. LACTRIMS

  25. CAN DO MS

  26. Multiple Sclerosis Foundation

  27. National MS Society

  28. Neuromyelitis Optica

  29. Welcome to Day Three at CMSC

  30. Ashley trying on the WalkAide Device

  31. BG-12 for People with MS

  32. Benefits of Treatments for Multiple Sclerosis

  33. Genetics and Multiple Sclerosis

  34. Motivation for People with MS

  35. Smoking and MS

  36. MS Nurses in Multiple Sclerosis

  37. Gilenya Risk and Support Program

  38. Helpful Information from the MSAA

  39. Flu like Symptoms with Interferon Beta Therapy

  40. Below the Belt Issues in People with MS

  41. The Effects of a Creative Arts Program on Individuals with Multiple Sclerosis

  42. What is Spasticity

  43. Caregivers of People with MS

  44. Bladder Issues in MS

  45. Marijuana and MS

  46. Changing your DMD

  47. Welcome to Day Two at CMSC

  48. Overview of Day 1 at CMSC

  49. Mimickers of MS

  50. How does the FES (Functional Electrical Stimulation) work?

  51. What is FES (Functional Electrical Stimulation)

  52. VA Case Management in MS

  53. Cognitive Impairment in People with MS

  54. What is CMSC

  55. Dr Kantor's Introduction to CMSC

  56. MSWorld's CMSC 2012 Meeting Intro

  57. MSF Cruise For A Cause Summary

  58. MSF Cruise For A Cause - Introduction

  59. AAN Summary

  60. Oral Teriflunomide with Mark Freedman

  61. Update on Disease Freedom

  62. Low Dose Naltrexone (LDN)

  63. What Do Neurologists Want To Hear

  64. Ampyra and Side Effects

  65. Remyelination

  66. Stem Cell Update

  67. Primary Progressive MS Patients

  68. MS Rehab

  69. BG12 Approval

  70. CareMS Trial with Dr Edward Fox

  71. Ashley and Omi's Update on the MS Exhibits at the AAN

  72. Disease Activity Free Trial

  73. Clinical Trial TEMSO

  74. TYSABRI AND PML

  75. Disease Freedom

  76. Clinical Trial BENEFIT

  77. The Prevalence of MS in Different Cultures

  78. Cognitive Dysfunction in MS

  79. MRI Changes in MS

  80. Improving Care Worldwide

  81. But You Look So Good

  82. Care MS I Trial

  83. Spinal Cord and MS

  84. CONFIRM Trial

  85. Epidemiology of MS

  86. The Importance of Lumbar Punctures in MS

  87. Update on Gilenya

  88. Trial Update on ADVANCE

  89. Trial on Treated RRMS Patients

  90. Symptoms in MS with Dr Jack Burks

  91. Educating Others About MS

  92. Tremor and MS

  93. Spasticity and Dystonia

  94. MS and Movement Disorders

  95. Education about MS

  96. Concussions and MS

  97. Migraines and MS

  98. The Frontline of MS

  99. Society and MS